Trifecta™ Bioprostheses: Evaluation of the safety based of degenerations according to the VARC-3 classification

1Hospital Pharmacy, 2Cardiac Surgery Department and 3Cardiology Department Amiens-Picardie University Hospital, Amiens, France.

BACKGROUND AND IMPORTANCE

In 2021, cardiologists reported to the medical-devices-vigilance sector serious incidents in four patients with a first-generation Trifecta™ bioprosthesis that resulted in three aortic valve replacement and one death. 
→ The question of the degeneration of their bioprosthesis arose.

AIM AND OBJECTIVES

Evaluate the intrinsic imputability of Trifecta™ for dysfunction according to the VARC-3 classification in patients implanted and to reassess their referencing in our center.

MATERIALS AND METHODS

1 Realisation of a retrospective, single-center and observational study of computerized patient records between February 4, 2011 date of our center’s first implantation, and December 31, 2016 to have 5 years of follow-up per patient. This study was approved by our local research department.

2 Extraction of Trifecta™ valves and data related to the implantation from the traceability software. The collection of echographic and clinical follow-up data were based on the computerized patient records with an extended follow-up period until March 31, 2022.

3 Classification of dysfunctions according to the VARC-3 classification criteria1: structural valve deterioration (SVD), non-structural valve dysfunction (NSVD), thrombosis and endocarditis.

RESULTS

- Average age: 73.0 (± 9.15) years, 60.7% male
- 382 bioprostheses Trifecta™ implanted in 378 patients
- Perioperative deaths: 15 patients
- Missing data: 253 patients
- Conclusive data: 114 patients
- Device success: 50 patients
- Bioprothetic valve dysfunction: 64 patients
- Mean follow-up time for patients with a properly functioning bioprosthesis: 6.6 years
- Aortic valve replacement: 31 patients during the follow-up period
- 4 of whom had a 2nd Trifecta™ during the study period
- SVD n = 34
- Endocarditis n = 20
- NSVD n = 10
- NSVD were classified as:
  - 8 paravalvular regurgitations
  - 2 prosthesis-patient mismatches

CONCLUSION AND RELEVANCE

The classification of failures according to VARC-3 allowed us to confirm the intrinsic imputability of the Trifecta™ bioprostheses regarding to the number of SVD-type dysfunctions. Although this study has limitations, it shows the understatement of medical-devices-vigilance cases by the medical staff. The 64 files with dysfunctions were transmitted to the national health authority. The patients will be reviewed to complete the data and perform an echographic follow-up.

According to the manufacturer, degenerations could be related to the expansion system that was improved in the second-generation Trifecta™ marketed in 2016. Since this study, the Trifecta™ has been removed from the hospital formulary.

Nowadays, the French High Authority for Health has removed these bioprostheses from the list of health products financed as hospitalization services mentioned in article L.165-112 and R. 165-493 of the social security code on the basis of a new safety assessment4. These articles condition the purchase of this bioprosthesis by health care institutions. Studies have shown that these valves are less durable than other bioprostheses.

REFERENCES

2 Code de la santé publique - Article L165-11
3 Code de la santé publique - Article R165-49